Hutch News

T cell diversity as a measure of immune recovery following CBT

T cell diversity as a measure of immune recovery following CBT

From the Cord Blood Group and colleagues, Clinical Research Division
Science SpotlightDecember 21, 2020
Targeted single-cell RNA sequencing maximizes cellular information at a lower cost

Targeted single-cell RNA sequencing maximizes cellular information at a lower cost

From the Gottardo, Newell, and Prlic labs, Vaccine and Infectious Disease Division
Science SpotlightMay 18, 2020
A cheaper way to study the immune system, one cell at a time

A cheaper way to study the immune system, one cell at a time

Scientists describe a more efficient way to sequence individual cells and visualize the massive amount of data that ensues
Hutch NewsApril 07, 2020
‘Let the cells tell the story’

‘Let the cells tell the story’

New tech is giving scientists unprecedented insights into single cells’ inner workings
Hutch NewsDecember 24, 2018
Finding branchpoint needles in a haystack of sequencing data

Finding branchpoint needles in a haystack of sequencing data

From the Bradley Lab, Basic Sciences & Public Health Sciences Divisions
Science SpotlightJuly 16, 2018
A slapdash virus relies on quantity over quality to achieve successful infections

A slapdash virus relies on quantity over quality to achieve successful infections

From the Bloom Lab, Basic Sciences Division
Science SpotlightApril 16, 2018
High-throughput sequencing outpaces flow cytometry for earliest detection of cancer relapse

High-throughput sequencing outpaces flow cytometry for earliest detection of cancer relapse

Next-generation, high-speed DNA-decoding technology detects minimal residual disease in nearly double the number of leukemia patients than current gold standard method
Hutch NewsMay 21, 2012
Detecting earliest signs of cancer relapse: Study finds high-throughput sequencing outpaces flow cytometry

Detecting earliest signs of cancer relapse: Study finds high-throughput sequencing outpaces flow cytometry

Next-generation, high-speed DNA-decoding technology detects minimal residual disease in nearly double the number of leukemia patients than current gold standard method
News ReleasesMay 16, 2012